Children's Health and the Environment WHO Training Package for the Health Sector World Health Organization
Facing the COVID-19 (new coronavirus disease) pandemic, the countries of the world must take decisive action to stop the spread of the virus. In these critical circumstances, it is es- sential that everyone is informed about other health risks and hazards so that they can stay safe and healthy.
The... following factsheet provides important information that you should know about alcohol consumption and COVID-19. It addresses, among other things, the misinformation that is being spread through social media and other communication channels about alcohol and COVID-19.
more
Q10: Are antidepressants (Tricyclic antidepressants (TCA), Selective serotonin reuptake inhibitors (SSRIs)) effective and safe in children 6-12 years of age with depressive episode/disorder?
Session outline
•Introduction to dementia
•Assessment of dementia
•Management of dementia
•Follow-up
•Review
Global COVID-19 Clinical Platform: Case Record Form for suspected cases of Multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19
Q3: For behavioural and psychological symptoms in people with dementia, do following drugs, when compared to placebo/comparator, produce benefits/harm in the specified outcomes?
The Interim Guidance on Cholera Rapid Diagnostic Tests (RDTs) by the Global Task Force on Cholera Control (GTFCC) provides recommendations for using RDTs to detect cholera in areas with limited laboratory capacity. It highlights the advantages of RDTs, such as rapid detection (within 30 minutes), ea...se of use by non-laboratory personnel, and their role in early outbreak identification and surveillance. However, it emphasizes that RDTs should not replace culture or PCR testing, as they vary in sensitivity (58-100%) and specificity (60-100%). The document advises on proper test selection, storage, training, and integration into national surveillance systems to enhance cholera response efforts.
more
Standard Treatment Guideline
Weekly Epidemiological Record (WER), 17 September 2021, Vol. 96, No. 37 (pp. 445-460)
This Implementation Kit (I-Kit), developed by the Health Communication Capacity Collaborative (HC3), helps national and local stakeholders to design country-specific social and behavioural change communication (SBCC) campaigns that address the threat posed by substandard, spurious, falsified and fal...sely labelled (SSFFC) malaria medicines. These poor-quality medicines endanger lives by failing to treat malaria effectively, undermine health systems, and contribute to drug resistance.
The I-Kit provides practical guidance and resources in six sections, including global examples, campaign design elements, media engagement strategies and tools for knowledge sharing. It is intended for health promotion officers, drug regulators, communication specialists and global health partners. Drawing heavily on experiences in Nigeria, the I-Kit promotes evidence-based, context-sensitive SBCC interventions to safeguard communities against SSFFC malaria medicines and enhance treatment outcomes.
more
SIXTY-FIFTH WORLD HEALTH ASSEMBLY WHA 65.21